Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial
Zhaowei Chen, Jijia Hu, Zongwei Zhang, Shan Jiang, Shoumeng Han, Dandan Yan, Ruhong Zhuang, Ben Hu, Zhan Zhang
doi:10.1101/2020.03.22.20040758
Aims: Studies have indicated that chloroquine (CQ) shows antagonism against COVID-19 in vitro. However, evidence regarding its effects in patients is limited. This study aims to evaluate the efficacy of hydroxychloroquine (HCQ) in the treatment of patients with COVID-19.
Main methods: From February 4 to February 28, 2020, 62 patients suffering from COVID-19 were diagnosed and admitted to Renmin Hospital of Wuhan University. All participants were randomized in a parallel-group trial, 31 patients were assigned to receive an additional 5-day HCQ (400 mg/d) treatment, Time to clinical recovery (TTCR), clinical characteristics, and radiological results were assessed at baseline and 5 days after treatment to evaluate the effect of HCQ.
Key findings: For the 62 COVID-19 patients, 46.8% (29 of 62) were male and 53.2% (33 of 62) were female, the mean age was 44.7 (15.3) years. No difference in the age and sex distribution between the control group and the HCQ group. But for TTCR, the body temperature recovery time and the cough .
Ethics approval and consent to participate The clinical research protocol was reviewed and approved by the Ethics Committee in Renmin Hospital of Wuhan University (Wuhan, China). All research procedures adhered to the tenets of the Declaration of Helsinki. This trial has been registered in the Chinese Clinical Trial Registry, the unique identifier: ChiCTR2000029559.
Conflict of Interest Disclosures All authors declare no competing interests.
Author Contributions ZZ designed this study and major in the clinical management of patients, data collection, data analysis, and writing of the first draft. ZC and JH improved the data analysis and finished the manuscript. SJ helped the clinical management of patients. SH had roles in data collection and interpretation. ZZ and DY had roles in data analysis and data interpretation, RZ and BH helped the data collection. All authors reviewed and approved the final version of the manuscript.
References
Akpovwa, Chloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivity, Cell Biochem Funct,
doi:10.1002/cbf.3182Chen, Xiong, Bao, Shi, Convalescent plasma as a potential therapy for COVID-19
Chen, Zhou, Dong, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, The Lancet,
doi:10.1016/S0140-6736(20)30211-7Colson, Rolain, Lagier, Brouqui, Raoult, Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
Conti, Ronconi, Caraffa, Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies
Gao, Tian, Yang, Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends,
doi:10.5582/bst.2020.01047Gorbalenya, Baker, Baric, Severe acute respiratory syndrome-related coronavirus: The species and its viruses -a statement of the Coronavirus Study Group, bioRxiv
Gordon, Amissah-Arthur, Gayed, The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults, Rheumatology,
doi:10.1093/rheumatology/kex286Keyaerts, Vijgen, Maes, Neyts, Ranst, In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine, Biochem. Biophys. Res. Commun,
doi:10.1016/j.bbrc.2004.08.085Li, Guan, Wu, Early Transmission Dynamics in Wuhan, China, of Novel . Coronavirus-Infected Pneumonia, The New England journal of medicine,
doi:10.1101/2020.02.07.937862Liu, Li, Liu, Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients, medRxiv,
doi:10.1101/2020.02.16.20023671Ma, Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases, J Antimicrob Chemother,
doi:10.1093/jac/dkv018Radke, Kingery, Maakestad, Krasowski, Diagnostic pitfalls and laboratory test interference after hydroxychloroquine intoxication: A case report, Toxicol Rep,
doi:10.1016/j.toxrep.2019.10.006Rainsford, Parke, Clifford-Rashotte, Kean, Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases, Inflammopharmacology,
doi:10.1007/s10787-015-0239-ySchrezenmeier, Dorner, Mechanisms of action of hydroxychloroquine and chloroquine: . implications for rheumatology, Nat Rev Rheumatol,
doi:10.1038/s41584-020-0372-xVincent, Bergeron, Benjannet, Chloroquine is a potent inhibitor of SARS coronavirus infection and spread, Virol J,
doi:10.1186/1743-422X-2-69Wang, Cao, Zhang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res,
doi:10.1038/s41422-020-0282-0DOI record:
{
"DOI": "10.1101/2020.03.22.20040758",
"URL": "http://dx.doi.org/10.1101/2020.03.22.20040758",
"abstract": "<jats:title>Abstract</jats:title><jats:sec><jats:title>Aims</jats:title><jats:p>Studies have indicated that chloroquine (CQ) shows antagonism against COVID-19 in vitro. However, evidence regarding its effects in patients is limited. This study aims to evaluate the efficacy of hydroxychloroquine (HCQ) in the treatment of patients with COVID-19.</jats:p></jats:sec><jats:sec><jats:title>Main methods</jats:title><jats:p>From February 4 to February 28, 2020, 62 patients suffering from COVID-19 were diagnosed and admitted to Renmin Hospital of Wuhan University. All participants were randomized in a parallel-group trial, 31 patients were assigned to receive an additional 5-day HCQ (400 mg/d) treatment, Time to clinical recovery (TTCR), clinical characteristics, and radiological results were assessed at baseline and 5 days after treatment to evaluate the effect of HCQ.</jats:p></jats:sec><jats:sec><jats:title>Key findings</jats:title><jats:p>For the 62 COVID-19 patients, 46.8% (29 of 62) were male and 53.2% (33 of 62) were female, the mean age was 44.7 (15.3) years. No difference in the age and sex distribution between the control group and the HCQ group. But for TTCR, the body temperature recovery time and the cough remission time were significantly shortened in the HCQ treatment group. Besides, a larger proportion of patients with improved pneumonia in the HCQ treatment group (80.6%, 25 of 31) compared with the control group (54.8%, 17 of 31). Notably, all 4 patients progressed to severe illness that occurred in the control group. However, there were 2 patients with mild adverse reactions in the HCQ treatment group. Significance: Among patients with COVID-19, the use of HCQ could significantly shorten TTCR and promote the absorption of pneumonia.</jats:p></jats:sec><jats:sec><jats:title>Significance</jats:title><jats:p>Among patients with COVID-19, the use of HCQ could significantly shorten TTCR and promote the absorption of pneumonia.</jats:p></jats:sec><jats:sec><jats:title>Trial registration</jats:title><jats:p>URL: <jats:ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"https://www.clinicaltrials.gov/\">https://www.clinicaltrials.gov/</jats:ext-link>. The unique identifier: ChiCTR2000029559.</jats:p></jats:sec>",
"accepted": {
"date-parts": [
[
2020,
4,
10
]
]
},
"author": [
{
"affiliation": [],
"family": "Chen",
"given": "Zhaowei",
"sequence": "first"
},
{
"ORCID": "http://orcid.org/0000-0002-8847-845X",
"affiliation": [],
"authenticated-orcid": false,
"family": "Hu",
"given": "Jijia",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Zhang",
"given": "Zongwei",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Jiang",
"given": "Shan",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Han",
"given": "Shoumeng",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Yan",
"given": "Dandan",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Zhuang",
"given": "Ruhong",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Hu",
"given": "Ben",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0002-4919-2846",
"affiliation": [],
"authenticated-orcid": false,
"family": "Zhang",
"given": "Zhan",
"sequence": "additional"
}
],
"container-title": [],
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2020,
3,
30
]
],
"date-time": "2020-03-30T20:39:20Z",
"timestamp": 1585600760000
},
"deposited": {
"date-parts": [
[
2020,
11,
21
]
],
"date-time": "2020-11-21T20:15:34Z",
"timestamp": 1605989734000
},
"group-title": "Epidemiology",
"indexed": {
"date-parts": [
[
2024,
4,
1
]
],
"date-time": "2024-04-01T17:51:06Z",
"timestamp": 1711993866781
},
"institution": [
{
"name": "medRxiv"
}
],
"is-referenced-by-count": 369,
"issued": {
"date-parts": [
[
2020,
3,
30
]
]
},
"link": [
{
"URL": "https://syndication.highwire.org/content/doi/10.1101/2020.03.22.20040758",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "246",
"original-title": [],
"posted": {
"date-parts": [
[
2020,
3,
30
]
]
},
"prefix": "10.1101",
"published": {
"date-parts": [
[
2020,
3,
30
]
]
},
"publisher": "Cold Spring Harbor Laboratory",
"reference": [
{
"DOI": "10.1056/NEJMoa2001017",
"doi-asserted-by": "publisher",
"key": "2020112112151140000_2020.03.22.20040758v3.1"
},
{
"DOI": "10.1101/2020.02.07.937862",
"doi-asserted-by": "crossref",
"key": "2020112112151140000_2020.03.22.20040758v3.2",
"unstructured": "Gorbalenya AE , Baker SC , Baric RS , et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group. bioRxiv. 2020:2020-2022."
},
{
"DOI": "10.1101/2020.02.07.937862",
"doi-asserted-by": "crossref",
"key": "2020112112151140000_2020.03.22.20040758v3.3",
"unstructured": "Li Q , Guan X , Wu P , et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. The New England journal of medicine. 2020. DOI: https://doi.org/10.1101/2020.02.07.937862."
},
{
"DOI": "10.1016/S0140-6736(20)30211-7",
"doi-asserted-by": "publisher",
"key": "2020112112151140000_2020.03.22.20040758v3.4"
},
{
"key": "2020112112151140000_2020.03.22.20040758v3.5",
"unstructured": "World Health Organization. COVID-2019 situation reports-59. https://www.who.int/docs/default-source/coronaviruse/situationreports/20200319-sitrep-59-covid-19.pdf?sfvrsn=c3dcdef9_2."
},
{
"DOI": "10.1016/S0140-6736(20)30185-9",
"doi-asserted-by": "publisher",
"key": "2020112112151140000_2020.03.22.20040758v3.6"
},
{
"DOI": "10.1038/s41422-020-0282-0",
"doi-asserted-by": "publisher",
"key": "2020112112151140000_2020.03.22.20040758v3.7"
},
{
"DOI": "10.5582/bst.2020.01047",
"doi-asserted-by": "publisher",
"key": "2020112112151140000_2020.03.22.20040758v3.8"
},
{
"DOI": "10.1016/j.ijantimicag.2020.105932",
"doi-asserted-by": "publisher",
"key": "2020112112151140000_2020.03.22.20040758v3.9"
},
{
"key": "2020112112151140000_2020.03.22.20040758v3.10",
"unstructured": "The U.S. Food and Drug Administration (FDA). Coronavirus (COVID-19) Update: FDA Continues to Facilitate Development of Treatments. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-continues-facilitate-development-treatments."
},
{
"DOI": "10.1007/s10787-015-0239-y",
"doi-asserted-by": "publisher",
"key": "2020112112151140000_2020.03.22.20040758v3.11"
},
{
"DOI": "10.1093/rheumatology/kex286",
"doi-asserted-by": "publisher",
"key": "2020112112151140000_2020.03.22.20040758v3.12"
},
{
"DOI": "10.1038/s41584-020-0372-x",
"doi-asserted-by": "publisher",
"key": "2020112112151140000_2020.03.22.20040758v3.13"
},
{
"DOI": "10.1002/cbf.3182",
"doi-asserted-by": "publisher",
"key": "2020112112151140000_2020.03.22.20040758v3.14"
},
{
"DOI": "10.1016/j.bbrc.2004.08.085",
"doi-asserted-by": "publisher",
"key": "2020112112151140000_2020.03.22.20040758v3.15"
},
{
"DOI": "10.1186/1743-422X-2-69",
"doi-asserted-by": "publisher",
"key": "2020112112151140000_2020.03.22.20040758v3.16"
},
{
"DOI": "10.1093/jac/dkv018",
"doi-asserted-by": "publisher",
"key": "2020112112151140000_2020.03.22.20040758v3.17"
},
{
"DOI": "10.1101/2020.02.16.20023671",
"doi-asserted-by": "crossref",
"key": "2020112112151140000_2020.03.22.20040758v3.18",
"unstructured": "J Liu , S Li , J Liu . et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. medRxiv 2020.02.16.20023671; DOI: https://doi.org/10.1101/2020.02.16.20023671."
},
{
"DOI": "10.23812/CONTI-E",
"doi-asserted-by": "publisher",
"key": "2020112112151140000_2020.03.22.20040758v3.19"
},
{
"DOI": "10.1016/S1473-3099(20)30141-9",
"doi-asserted-by": "publisher",
"key": "2020112112151140000_2020.03.22.20040758v3.20"
},
{
"DOI": "10.1056/NEJMicm1304542",
"doi-asserted-by": "publisher",
"key": "2020112112151140000_2020.03.22.20040758v3.21"
},
{
"DOI": "10.1016/j.toxrep.2019.10.006",
"doi-asserted-by": "publisher",
"key": "2020112112151140000_2020.03.22.20040758v3.22"
}
],
"reference-count": 22,
"references-count": 22,
"relation": {
"has-review": [
{
"asserted-by": "object",
"id": "10.14322/PUBLONS.R7741504",
"id-type": "doi"
}
]
},
"resource": {
"primary": {
"URL": "http://medrxiv.org/lookup/doi/10.1101/2020.03.22.20040758"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subtitle": [],
"subtype": "preprint",
"title": "Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial",
"type": "posted-content"
}
